Lenvatinib Plus Pembrolizumab versus Doxorubicin for Advanced or Recurrent Endometrial Cancer with Short Treatment-Free Intervals Following First-Line Carboplatin Plus Paclitaxel

Lenvatinib Plus Pembrolizumab versus Doxorubicin for Advanced or Recurrent Endometrial Cancer with Short Treatment-Free Intervals Following First-Line Carboplatin Plus Paclitaxel

: The treatment-free interval is a significant predictor of worse prognosis and poor response rates of the second-line treatment in patients with carboplatin and paclitaxel (PT)-pretreated, advanced, or recurrent endometrial cancer (EC). Whether lenvatinib plus pembrolizumab still confers a survival...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical medicine 2024-09, Vol.13 (19), p.5670
Hauptverfasser: Wang, Shao-Jing, Chen, Hsin-Hua, Sun, Lou, Shih, Yu-Hsiang, Lu, Ting-Fang, Chen, Yen-Fu, Fan, Chun-Ting, Hsu, Shih-Tien, Liu, Chin-Ku, Hwang, Sheau-Feng, Lu, Chien-Hsing
Format: Artikel
Sprache:eng
Schlagworte:
Cancer therapies
Chemotherapy
Comparative analysis
Dosage and administration
Doxorubicin
Drug therapy
Drug therapy, Combination
Endometrial cancer
Growth factors
Hematology
Kinases
Medical prognosis
Metastasis
Neutropenia
Patient outcomes
Response rates
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:: The treatment-free interval is a significant predictor of worse prognosis and poor response rates of the second-line treatment in patients with carboplatin and paclitaxel (PT)-pretreated, advanced, or recurrent endometrial cancer (EC). Whether lenvatinib plus pembrolizumab still confers a survival benefit compared with doxorubicin in patients with platinum-free intervals of
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm13195670